112 related articles for article (PubMed ID: 8114606)
1. Cromakalim and cicletanine against pacing-induced myocardial ischemia in conscious rabbits.
Szilvassy Z; Koltai M; Ferdinandy P; Jakab I; Lonovics J; Tarrade T; Allard M; Braquet PG
Life Sci; 1994; 54(9):PL125-30. PubMed ID: 8114606
[TBL] [Abstract][Full Text] [Related]
2. Cicletanine attenuates overdrive pacing-induced global myocardial ischemia in rabbits: possible role of cardiac cyclic nucleotides.
Szilvassy Z; Jakab I; Bor P; Koltai M; Tarrade T; Esanu A; Braquet PG; Lonovics J
Coron Artery Dis; 1993 May; 4(5):443-52. PubMed ID: 8261221
[TBL] [Abstract][Full Text] [Related]
3. KATP channel modulation in working rat hearts with coronary occlusion: effects of cromakalim, cicletanine, and glibenclamide.
Ferdinandy P; Szilvássy Z; Droy-Lefaix MT; Tarrade T; Koltai M
Cardiovasc Res; 1995 Nov; 30(5):781-7. PubMed ID: 8595627
[TBL] [Abstract][Full Text] [Related]
4. Ventricular overdrive pacing-induced preconditioning and no-flow ischemia-induced preconditioning in isolated working rat hearts.
Ferdinandy P; Szilvássy Z; Koltai M; Dux L
J Cardiovasc Pharmacol; 1995 Jan; 25(1):97-104. PubMed ID: 7723361
[TBL] [Abstract][Full Text] [Related]
5. Zaprinast, cicletanine, and verapamil attenuate overdrive pacing-induced myocardial ischemia in conscious rabbits.
Szilvassy Z; Jakab I; Ferdinandy P; Koltai M; Lonovics J; Tarrade T; Braquet PG
Life Sci; 1993; 53(1):PL13-8. PubMed ID: 8390593
[TBL] [Abstract][Full Text] [Related]
6. Activation of ATP-sensitive K+ channels by cromakalim. Effects on cellular K+ loss and cardiac function in ischemic and reperfused mammalian ventricle.
Venkatesh N; Stuart JS; Lamp ST; Alexander LD; Weiss JN
Circ Res; 1992 Dec; 71(6):1324-33. PubMed ID: 1423930
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the relaxing effects of cicletanine and cromakalim on vascular smooth muscle.
Deitmer P; Golenhofen K; Noack T
J Cardiovasc Pharmacol; 1992 Jul; 20(1):35-42. PubMed ID: 1383629
[TBL] [Abstract][Full Text] [Related]
8. Analysis of pulmonary and systemic vascular responses to cromakalim, an activator of K+ATP channels.
Minkes RK; Kvamme P; Higuera TR; Nossaman BD; Kadowitz PJ
Am J Physiol; 1991 Mar; 260(3 Pt 2):H957-66. PubMed ID: 1825747
[TBL] [Abstract][Full Text] [Related]
9. A comparison between the effects of BMS-180448, a novel K+ channel opener, and cromakalim in rat and dog.
D'Alonzo AJ; Darbenzio RB; Sewter JC; Hess TA; Grover GJ; Sleph PG; Normandin DE; Lodge NJ
Eur J Pharmacol; 1995 Dec; 294(1):271-80. PubMed ID: 8788441
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular effects of the novel potassium channel opener UR-8225.
Tamargo J; Pérez O; Delpón E; García-Rafanell J; Gómez L; Cavalcanti F
J Cardiovasc Pharmacol; 1995 Aug; 26(2):295-305. PubMed ID: 7475055
[TBL] [Abstract][Full Text] [Related]
11. Cardioprotection with the KATP opener cromakalim is not correlated with ischemic myocardial action potential duration.
Grover GJ; D'Alonzo AJ; Parham CS; Darbenzio RB
J Cardiovasc Pharmacol; 1995 Jul; 26(1):145-52. PubMed ID: 7564356
[TBL] [Abstract][Full Text] [Related]
12. Ventricular overdrive pacing-induced anti-ischemic effect: a conscious rabbit model of preconditioning.
Szilvassy Z; Ferdinandy P; Bor P; Jakab I; Lonovics J; Koltai M
Am J Physiol; 1994 May; 266(5 Pt 2):H2033-41. PubMed ID: 8203601
[TBL] [Abstract][Full Text] [Related]
13. Effect of cicletanine on overpacing-induced ST-segment elevation in conscious rabbits. A comparison with verapamil.
Szilvássy Z; Koltai M; Szekeres L; Tarrade T; Braquet P
Eur J Pharmacol; 1991 Jul; 199(3):383-6. PubMed ID: 1915586
[TBL] [Abstract][Full Text] [Related]
14. Effects of ATP-dependent K+ channel modulators on an ischemia-reperfusion rabbit isolated heart model with programmed electrical stimulation.
Bellemin-Baurreau J; Poizot A; Hicks PE; Rochette L; Armstrong JM
Eur J Pharmacol; 1994 Apr; 256(2):115-24. PubMed ID: 8050462
[TBL] [Abstract][Full Text] [Related]
15. Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts?
Tosaki A; Szerdahelyi P; Engelman RM; Das DK
J Pharmacol Exp Ther; 1993 Dec; 267(3):1355-62. PubMed ID: 8263798
[TBL] [Abstract][Full Text] [Related]
16. Beneficial cardiac effects of cicletanine in conscious rabbits with metabolic syndrome.
Drimba L; Hegedüs C; Yin D; Sári R; Németh J; Szilvássy Z; Peitl B
J Cardiovasc Pharmacol; 2012 Aug; 60(2):208-18. PubMed ID: 22622233
[TBL] [Abstract][Full Text] [Related]
17. In vivo cardiac electrophysiologic effects of RWJ 29009, a new potassium-channel activator, in comparison to cromakalim and nicardipine.
Damiano BP; Stump GL; Cheung WM; Salata JJ
J Cardiovasc Pharmacol; 1993 Jul; 22(1):143-52. PubMed ID: 7690086
[TBL] [Abstract][Full Text] [Related]
18. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent.
Katz LB; Giardino EC; Salata JJ; Moore JB; Falotico R
J Pharmacol Exp Ther; 1993 Nov; 267(2):648-56. PubMed ID: 8246137
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular effects of KRN2391 in anesthetized dogs: a comparison with cromakalim and nitroglycerin.
Kaneta S; Yokoyama T; Izumi H; Izawa T; Ogawa N
Arch Int Pharmacodyn Ther; 1994; 327(2):184-93. PubMed ID: 7979827
[TBL] [Abstract][Full Text] [Related]
20. Combined administration of an IK(ATP) activator and Ito blocker increases coronary flow independently of effects on heart rate, QT interval, and ischaemia-induced ventricular fibrillation in rats.
Rees SA; Tsuchihashi K; Hearse DJ; Curtis MJ
J Cardiovasc Pharmacol; 1993 Sep; 22(3):343-9. PubMed ID: 7504122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
